The role of PKA and PKCε pathways in prostaglandin E2-mediated hypernociception
Version of Record online: 13 FEB 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Pharmacology
Volume 156, Issue 5, pages 826–834, March 2009
How to Cite
Sachs, D., Villarreal, C., Cunha, F., Parada, C. and Ferreira, S. (2009), The role of PKA and PKCε pathways in prostaglandin E2-mediated hypernociception. British Journal of Pharmacology, 156: 826–834. doi: 10.1111/j.1476-5381.2008.00093.x
- Issue online: 26 MAR 2009
- Version of Record online: 13 FEB 2009
- Received 7 July 2008; revised 29 September 2008; accepted 6 November 2008
- PGE2 and rat mechanical hypernociception
Background and purpose: Protein kinase (PK) A and the ε isoform of PKC (PKCε) are involved in the development of hypernociception (increased sensitivity to noxious or innocuous stimuli) in several animal models of acute and persistent inflammatory pain. The present study evaluated the contribution of PKA and PKCε to the development of prostaglandin E2 (PGE2)-induced mechanical hypernociception.
Experimental approach: Prostaglandin E2-induced mechanical hypernociception was assessed by constant pressure rat paw test. The activation of PKA or PKCε was evaluated by radioactive enzymic assay in the dorsal root ganglia (DRG) of sensory neurons from the hind paws.
Key results: Hypernociception induced by PGE2 (100 ng) by intraplantar (i.pl.) injection, was reduced by i.pl. treatment with inhibitors of PKA [A-kinase-anchoring protein St-Ht31 inhibitor peptide (AKAPI)], PKCε (PKCεI) or adenylyl cyclase. PKA activity was essential in the early phase of the induction of hypernociception, whereas PKC activity was involved in the maintenance of the later phase of hypernociception. In the DRG (L4-L5), activity of PKA increased at 30 min after injection of PGE2 but PKC activity increased only after 180 min. Moreover, i.pl. injection of the catalytic subunit of PKA induced hypernociception which was markedly reduced by pretreatment with an inhibitor of PKCε, while the hypernociception induced by paw injection of PKCε agonist was not affected by an inhibitor of PKA (AKAPI).
Conclusions and implications: Taken together, these findings are consistent with the suggestion that PKA activates PKCε, which is a novel mechanism of interaction between these kinases during the development of PGE2-induced mechanical hypernociception.